# TROPION-PanTumor03 (NCT05489211)

> Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

No report yet. It can be ordered.

- Drugs tested: datopotamab deruxtecan; datopotamab deruxtecan plus capecitabine; datopotamab deruxtecan plus 5-fluorouracil
- Indication: advanced/metastatic solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05489211
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: Endometrial Cancer; Gastric Cancer; Metastatic Castration-resistant Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Urothelial Cancer; Biliary Tract Cancer
- Interventions: Datopotamab deruxtecan (Dato-DXd); Capecitabine; 5-Fluorouracil; Volrustomig; Carboplatin; Bevacizumab; Rilvegostomig; Prednisone/ prednisolone; Cisplatin
- Enrollment: 454
- Primary outcome: Objective response rate (ORR)
- Primary outcome: The number of subjects with adverse events/serious adverse events
- Primary outcome: PSA50 response (Substudy 3 only)
- Primary outcome: Progression free survival (PFS) response (Substudy 4C only)

## Indexed commentary on TROPION-PanTumor03 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X
- 2 YouTube videos
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=tropion-pantumor03-nct05489211

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05489211", "email": "<work email>"}; the inbox owner confirms by the emailed link.